ArticleJournal of ovarian research2025
A TAp63alpha truncating variant associated with primary ovarian insufficiency lowers the cellular apoptotic rate.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary ovarian insufficiency (POI) is a complex endocrine disorder with impairment of ovarian function before the age of 40 that can associate with mutations in TAp63alpha (TAp63α), a transcription factor essential for maintaining genome integrity in the female germline. Variants located in the C-terminal can constitutively self-activate TAp63α and induce oocyte apoptosis, resulting in POI. This research examined the involvement of the R643* truncating variant of TAp63α in the development of POI.
methodsExperiments were performed in the human osteosarcoma-derived SAOS-2 cell line, a non-germline in vitro model selected due to its lack of endogenous TAp63α expression. This cell line cannot fully recapitulate the ovarian follicle microenvironment; however, the R643* variant was investigated alongside the previously validated R594* POI-related variant to confirm the robustness of the methodology. DNA damage was induced using Doxorubicin treatment, and subsequent analyses were performed using Western immunoblotting, luciferase assays, quantitative PCR, and flow cytometry.
resultsThe R643* variant of the TAp63α protein was expressed at minimal RNA and protein levels in the transfected SAOS-2 cells (p < 0.001). The overexpression of the TAp63α mutant R643* in SAOS-2 cells resulted in a significant alteration in the expression of target genes. Specifically, BAX expression was decreased (adjusted p = 0.0008), whereas the expression of IRF6, K14, WNT4, and MASPIN was significantly elevated (adjusted p < 0.0001). MDM2 expression also increased (adjusted p < 0.05). Notably, stable R643* variant expression increased cell survival following Doxorubicin treatment (adjusted p < 0.05).
conclusionsWe propose a new molecular mechanism for the induction of POI. Our in vitro characterization indicated that the R643* variant of TAp63α may increase the susceptibility of germ cells to DNA damage accumulation during the extended period of meiotic arrest, likely due to a decrease in apoptosis. Concurrently, it appears to stimulate pathways and genes driving uncontrolled follicular development and proliferation. The consequence of these combined effects would be the persistence of poorly competent oocytes, which ultimately leads to premature depletion of the follicular reserve. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.